Add to ORKGThe calcineurin inhibitor tacrolimus is used to preventorgan rejection following renal transplant. This drug is metabolized through the hepatic cytochrome P450 (CYP450) 3A enzymes, in particular, CYP3A4 and CYP3A5.1,2 A strong relationship between CYP3A5 genetic polymorphisms and th
1. Disposition of tacrolimus and its major metabolites, 13-O-desmethyl tacrolimus and 15-O-desmethyl...
Background and Aims: Tacrolimus is a macrolide immunosuppressant used for prevention of allograft re...
Tacrolimus (Tac) exhibits an interindividual pharmacokinetic variability that affects the dose requi...
Objective Tacrolimus is an immunosuppressive drug with narrow therapeutic range and wide interindivi...
The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy after solid o...
Lucy Chen,1 G V Ramesh Prasad2 1Kidney Transplant Program, St Michael’s Hospital, Toronto...
Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity. Tac pharmacokinetics vari...
Previous investigations of solid organ transplant patients treated with tacrolimus showed that indiv...
Tacrolimus (FK506) is a calcineurin inhibitor with a narrow therapeutic index that exhibits large in...
suppressant with considerable toxicity. Tac pharmaco-kinetics varies considerably between individual...
BACKGROUND: Cytochrome P450 3A5 (CYP3A5) and ABCB1 polymorphisms have been shown to influence tacrol...
AbstractPolymorphisms in the genes of drug-metabolizing enzymes have the potential to contribute to ...
CYP3A enzymes are involved in the metabolism of calcineurin inhibitor tacrolimus as well as vitamin ...
Background/Aim. Tacrolimus concentration-dose ratio as a potential therapeutic drug monitoring strat...
Tacrolimus, an immunosuppressant agent indicated for organ transplants, is commonly administered to ...
1. Disposition of tacrolimus and its major metabolites, 13-O-desmethyl tacrolimus and 15-O-desmethyl...
Background and Aims: Tacrolimus is a macrolide immunosuppressant used for prevention of allograft re...
Tacrolimus (Tac) exhibits an interindividual pharmacokinetic variability that affects the dose requi...
Objective Tacrolimus is an immunosuppressive drug with narrow therapeutic range and wide interindivi...
The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy after solid o...
Lucy Chen,1 G V Ramesh Prasad2 1Kidney Transplant Program, St Michael’s Hospital, Toronto...
Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity. Tac pharmacokinetics vari...
Previous investigations of solid organ transplant patients treated with tacrolimus showed that indiv...
Tacrolimus (FK506) is a calcineurin inhibitor with a narrow therapeutic index that exhibits large in...
suppressant with considerable toxicity. Tac pharmaco-kinetics varies considerably between individual...
BACKGROUND: Cytochrome P450 3A5 (CYP3A5) and ABCB1 polymorphisms have been shown to influence tacrol...
AbstractPolymorphisms in the genes of drug-metabolizing enzymes have the potential to contribute to ...
CYP3A enzymes are involved in the metabolism of calcineurin inhibitor tacrolimus as well as vitamin ...
Background/Aim. Tacrolimus concentration-dose ratio as a potential therapeutic drug monitoring strat...
Tacrolimus, an immunosuppressant agent indicated for organ transplants, is commonly administered to ...
1. Disposition of tacrolimus and its major metabolites, 13-O-desmethyl tacrolimus and 15-O-desmethyl...
Background and Aims: Tacrolimus is a macrolide immunosuppressant used for prevention of allograft re...
Tacrolimus (Tac) exhibits an interindividual pharmacokinetic variability that affects the dose requi...